COVID - 19NCT06787755
Persistent COVID-19 Symptoms in Minia
An observational study of COVID - 19, run by Fayoum University at 1 site in Egypt.
Trial summary
Objective This study aims to identify the nature and prevalence of persistent symptoms in patients discharged from Minya University hospitals in Egypt after recovery from COVID-19, the severity of these symptoms, and the possible risk factors associated with them. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- COVID - 19
- How many people
- 189 participants
- Where
- 1 siteEgypt
- Study dates
- 10 Mar 2021to 10 Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This is a cross-sectional observational retrospective survey study in which we collected information about any persistent or new symptoms after recovery from COVID-19. The average time after recovery from COVID was 6 months at the time of patient interviews, and the median duration of symptoms was 14 days. We collected various patient data including their medical history before COVID-19, treatments they received during their illness, and self-reported use of unprescribed antibiotics in home-isolated patients.
Who may be able to join
- Inclusion criteria Patients were included in this study if they tested positive for COVID-19 at the time of their illness (positive COVID-19 polymerase chain reaction [PCR] test) or if laboratory, clinical, and radiological criteria suggested the infection with COVID-19, and the severity of their symptoms ranged from asymptomatic to severe. Both hospitalized and non-hospitalized patients were included.
Who cannot join
- Exclusion criteria Patients excluded were frail or at the end of their life or had severe cognitive dysfunction, as well as patients <18 years of age.
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Persistent COVID-19 Symptoms in Minia, Upper Egypt: an Observational Cross-sectional Study
Objective This study aims to identify the nature and prevalence of persistent symptoms in patients discharged from Minya University hospitals in Egypt after recovery from COVID-19, the severity of these symptoms, and the possible risk factors associated with them.
Read the detailed description
This is a cross-sectional observational retrospective study. The study population included patients, both hospitalized and non-hospitalized, who were diagnosed with COVID-19. Demographic information, symptom severity, present comorbidities, and persistent COVID-19 symptoms were collected. SPSS software was used for the statistical analysis, and p-values less than 0.05 were considered significant.
- Conditions
- COVID - 19
- Keywords
- covid19, risk factors, self-medication
- Medical subject headings
- COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
Long COVID-19 has been an increasingly prevalent concern in the medical community for the last two years and is still a burden on the healthcare system worldwide
Constitutional and neurological manifestations are two of the most persistent symptoms. Lack of appropriate levels of awareness about long COVID-19, as well as the tendency of patients in this demographic to self-medicate are leading causes of the underreporting of long COVID-19 symptoms in this region
Measured: 2years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2025
- Study start10 Mar 2021
- Primary completion10 Sep 2023
- Study completion10 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for COVID - 19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 189 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fayoum University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marwa Kamal Ahmed Tolba, Fayoum University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06787755
- Sponsor's protocol ID
- : Persistent COVID-19 symptoms
- Status last verified
- Jan 2025
- First submitted
- 19 Jan 2025
- Last updated
- 22 Jan 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.
PubMed 33753937
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Persistent COVID-19 Symptoms in Minia, Upper Egypt: an Observational Cross-sectional Study
- ClinicalTrials.gov ID
- NCT06787755
- Acronym / sponsor ID
- : Persistent COVID-19 symptoms
- Conditions
- COVID - 19
- Keywords
- covid19, risk factors, self-medication
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 189 participants (actual)
- Lead sponsor
- Fayoum UniversityUniversity, hospital or other
- Study start
- 10 Mar 2021 (actual)
- Primary completion
- 10 Sep 2023 (actual)
- Study completion
- 10 Sep 2024 (actual)
- First posted
- 22 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective This study aims to identify the nature and prevalence of persistent symptoms in patients discharged from Minya University hospitals in Egypt after recovery from COVID-19, the severity of these symptoms, and the possible risk factors associated with them.
Detailed description
This is a cross-sectional observational retrospective study. The study population included patients, both hospitalized and non-hospitalized, who were diagnosed with COVID-19. Demographic information, symptom severity, present comorbidities, and persistent COVID-19 symptoms were collected. SPSS software was used for the statistical analysis, and p-values less than 0.05 were considered significant.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This is a cross-sectional observational retrospective survey study in which we collected information about any persistent or new symptoms after recovery from COVID-19. The average time after recovery from COVID was 6 months at the time of patient interviews, and the median duration of symptoms was 14 days. We collected various patient data including their medical history before COVID-19, treatments they received during their illness, and self-reported use of unprescribed antibiotics in home-isolated patients.
Key inclusion criteria (1 listed)
- Inclusion criteria Patients were included in this study if they tested positive for COVID-19 at the time of their illness (positive COVID-19 polymerase chain reaction [PCR] test) or if laboratory, clinical, and radiological criteria suggested the infection with COVID-19, and the severity of their symptoms ranged from asymptomatic to severe. Both hospitalized and non-hospitalized patients were included.
Key exclusion criteria (2 listed)
- Exclusion criteria Patients excluded were frail or at the end of their life or had severe cognitive dysfunction, as well as patients <18 years of age.
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Long COVID-19 has been an increasingly prevalent concern in the medical community for the last two years and is still a burden on the healthcare system worldwide
Time frame: 2years
Constitutional and neurological manifestations are two of the most persistent symptoms. Lack of appropriate levels of awareness about long COVID-19, as well as the tendency of patients in this demographic to self-medicate are leading causes of the underreporting of long COVID-19 symptoms in this region
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2025.
- Results publication: PubMed 33753937Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.
Related trials for COVID - 19
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruitingObservational study
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID - 19, run by Fayoum University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Long COVID-19 has been an increasingly prevalent concern in the medical community for the last two years and is still a burden on the healthcare system worldwide (time frame: 2years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06787755, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2025.